Narrative review assesses GLP-1 receptor agonists versus insulin for steroid-induced hyperglycemia and diabetes.

This narrative review examines the use of GLP-1 receptor agonists for managing steroid-induced hyperglycemia (SIH) and steroid-induced diabetes (SID). The analysis compares these agents against intensive insulin therapy as the standard comparator. The study population consists of patients diagnosed with SIH and SID, though the specific setting and total sample size are not reported in the source material.

Regarding primary outcomes, the review addresses the efficacy and safety of GLP-1 receptor agonists but does not provide exact numerical results or statistical comparisons. Consequently, no specific data points regarding glycemic control improvements or failure rates are available from this text. The review notes that safety and tolerability details, including adverse events, serious adverse events, and discontinuation rates, are not reported.

Key limitations of this evidence include the absence of quantitative data, the lack of a defined sample size, and the non-experimental design of a narrative review. These factors prevent the establishment of causal relationships or precise effect sizes. The practice relevance is constrained by the incomplete reporting of outcomes and the inability to generalize findings without primary trial data. Funding sources and potential conflicts of interest are not reported.

Clinicians should interpret these findings with caution. The evidence is insufficient to support definitive recommendations for GLP-1 receptor agonists over insulin in this specific population. Further high-quality research is required to clarify the role of these agents in managing steroid-induced glycemic disturbances.